- Home
- NXGL vs THAR Comparison
NXGL vs THAR Comparison
Compare NXGL & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- THAR
- Stock Information
- Founded
- NXGL 1997
- THAR 2017
- Country
- NXGL United States
- THAR United States
- Employees
- NXGL N/A
- THAR N/A
- Industry
- NXGL Medical/Dental Instruments
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- THAR Health Care
- Exchange
- NXGL Nasdaq
- THAR Nasdaq
- Market Cap
- NXGL 18.7M
- THAR 16.8M
- IPO Year
- NXGL 2021
- THAR 2022
- Fundamental
- Price
- NXGL N/A
- THAR $3.18
- Analyst Decision
- NXGL
- THAR Strong Buy
- Analyst Count
- NXGL 0
- THAR 1
- Target Price
- NXGL N/A
- THAR $17.00
- AVG Volume (30 Days)
- NXGL 44.2K
- THAR 644.6K
- Earning Date
- NXGL 11-12-2025
- THAR 11-06-2025
- Dividend Yield
- NXGL N/A
- THAR N/A
- EPS Growth
- NXGL N/A
- THAR N/A
- EPS
- NXGL N/A
- THAR N/A
- Revenue
- NXGL $11,672,000.00
- THAR N/A
- Revenue This Year
- NXGL $46.60
- THAR N/A
- Revenue Next Year
- NXGL $47.96
- THAR N/A
- P/E Ratio
- NXGL N/A
- THAR N/A
- Revenue Growth
- NXGL 133.02
- THAR N/A
- 52 Week Low
- NXGL $2.10
- THAR $0.95
- 52 Week High
- NXGL $5.10
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- NXGL N/A
- THAR 49.85
- Support Level
- NXGL N/A
- THAR $2.88
- Resistance Level
- NXGL N/A
- THAR $3.17
- Average True Range (ATR)
- NXGL 0.00
- THAR 0.31
- MACD
- NXGL 0.00
- THAR -0.00
- Stochastic Oscillator
- NXGL 0.00
- THAR 40.22
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.